CDSCO To Crack Down On Pharma Companies Not Using Barcodes

New Delhi: India’s drug regulatory authority will take action against Pharma companies that have failed to implement Barcodes or QR Codes on top 300 Medicine Brands.

The drug regulator is also considering setting up a joint task force for fighting the menace of spurious and adulterated drugs in the country, people in the know told ET.

In a recent meeting the drug regulator has asked states for “strict implementation” of barcodes. In a bid to weed out spurious drugs, the regulator had made it mandatory for the companies to have a barcode  on its label so that information such as manufacturing licence and batch number can be accessed upon scanning.

The top 300 brands of drugs included widely used analgesics, pain relievers, anti-platelet, vitamin supplements, blood-sugar lowering medicines and contraceptive tablets. “The move was to ensure authenticity of drugs and enable tracing,” added the person.

The brands identified by the National Pharmaceutical Pricing Authority (NPPA) include Dolo, Saridon Fabiflu, Ecosprin, Limcee, Sumo, Calpol, Corex syrup, Unwanted 72 and Thyronorm. They were shortlisted on the basis of their moving annual turnover value as per data from market research firm Pharmatrac.

Prior to this, the health ministry had asked the department of pharmaceuticals (DoP) to shortlist top 300 drugs so that necessary amendments can be made in the drug rules for its implementation.

QR codes can help in tracking and tracing the origin of drugs and minimise the chances of spurious, substandard or counterfeit drugs reaching patients.

Related Posts

Drugs & Cosmetics Rules | 60-Day Sample Testing Mandatory; Web-Host Reports: Bombay HC Orders Strict Action Against Erring Officers

The Bombay High Court (Nagpur Bench) last week expressed serious concern over repeated and systemic lapses by officers of the Drugs Department in adhering to the mandatory timelines prescribed under…

UP plans US FDA-accredited medical device testing lab

Lucknow:  In a major push to strengthen India’s medical device and pharmaceutical manufacturing ecosystem, the Uttar Pradesh govt is working on an ambitious project to establish a US FDA-accredited medical…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Drugs & Cosmetics Rules | 60-Day Sample Testing Mandatory; Web-Host Reports: Bombay HC Orders Strict Action Against Erring Officers

Drugs & Cosmetics Rules | 60-Day Sample Testing Mandatory; Web-Host Reports: Bombay HC Orders Strict Action Against Erring Officers

UP plans US FDA-accredited medical device testing lab

UP plans US FDA-accredited medical device testing lab

Patent rejected for MNC’s cancer drug, generics to follow

Patent rejected for MNC’s cancer drug, generics to follow

Zydus brings world’s first Nivolumab biosimilar to India

Zydus brings world’s first Nivolumab biosimilar to India

Dr Reddy’s set to start selling generic Ozempic in India at potentially half price

Dr Reddy’s set to start selling generic Ozempic in India at potentially half price

A total of 167 drug samples flagged as ‘not of standard quality’ in December 2025: Health Ministry

A total of 167 drug samples flagged as ‘not of standard quality’ in December 2025: Health Ministry